Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...
GlobalData on MSN18h
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trialShionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...
The transaction would allow Sanofi to solely focus on its more lucrative, drugs and vaccines business. The company's research-and-development spending increased 24% on-year in the last quarter in an ...
COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during ...
While many of the germs that cause this misery can circulate throughout the year, scientists think that the winter surge of ...
"This type of prevention can be very useful in controlling infection outbreaks and containing the bird flu pandemic," said an immunologist.
Learn about respiratory viruses during viral season and how to stay safe. Dr. Matthew Muller discusses COVID-19, RSV, influenza, and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback